Adults ≥ 40 years with CKD stages 1-5 and HF [LVEF > 40%; excluding end-stage renal disease (ESRD) or dialysis] receiving finerenone were compared with those on SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and stage 5 chronic kidney disease.